Document is current
Any future updates will be listed below
-
Authors
Lowry, Emily R. https://orcid.org/0000-0002-8412-3168
Patel, Tulsi https://orcid.org/0000-0002-3635-3567
Costa, Jonathon A.
Chang, Elizabeth
Tariq, Shahroz
Melikyan, Hranush
Davis, Ian https://orcid.org/0009-0005-0187-2921
Aziz, Siaresh
Ntermentzaki, Georgia
Lotti, Francesco
Wichterle, Hynek https://orcid.org/0000-0002-7817-0080
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS140764, K99NS121136, R01NS116141, R01NS116141, R01NS109217, R01NS140764)
Private funding was provided by Project ALS
- License Information
-
More Information
Article History
Received: 2 October 2023
Accepted: 24 June 2025
First Online: 12 August 2025
Competing interests
: E.R.L., T.P. and H.W. have filed a US provisional patent application for the use of ISL1/LHX3 in neurodegeneration (no. 63/359,527). The other authors declare no competing interests.
